Loading clinical trials...

UNKNOWNNA

In-stent Repair and Vessel Reaction of STEMI Patients With OCT

Assessment of In-stent Intimal Repair and Vessel Reaction After FirehawkTM Sirolimus Eluting Stent Implantation of STEMI Subjects - An Optical Coherence Tomography (OCT) Study

NCT04150016•Xijing Hospital

View on ClinicalTrials.gov

Summary

This study is a prospective, multi-center, non-inferior, randomized controlled clinical trial, aims to use optical Coherence tomography to observe the the early- and mid-stage vessel repair and neointimal proliferation. And to assess the safety and effectiveness of the Firehawk™ sirolimus target-eluting coronary stent system with abluminal grooves containing a biodegradable polymer (Firehawk™) comparing the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ST-elevation myocardial infarction (STEMI).

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•CI1. Subject must be 18 - 75 years of age; male or female without pregnancy.
•CI2. Subjects recently suffer from SETMI (from 20 minute to 12 hours), and ECG changes consistent with AMI:
•1mm elevation in more than 2 continuously leads, or; Newly developed LBBB, or;
•1mm depression in more than 2 continuously leads representing Posterior myocardial infarction) CI3. New, in situ and single or bifurcation lesion of target vessel. CI4. Subject only implanted one brand of stent. CI5. Subjects are eligible candidates for coronary artery bypass graft surgery (CABG).
•CI6. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed;
•AI1. At least one of the target lesions must be acute occlusion lesion, and Eligible for percutaneous coronary intervention (PCI), and Having a visually estimated diameter restenosis no less than 70% (or a visually estimated diameter restenosis no less than 50% with consistent clinical symptoms), TIMI blood flow no less than Grade I, and have a visually estimated reference diameter ≥2.25 mm and ≤4.0 mm.
•AI2. Target lesions must be able to pass through all target lesions (no severe tortuosity or calcification in proximal lesion).
•AI3. Target lesions of type A lesion defined by ACC/AHA must be successfully expanded (no severe calcification in target lesion).

Exclusion Criteria

•CE1. Subjects with Cardiogenic shock. CE2. Subjects with severe heart failure (NYHA classification ≥ 3) or LVEF\<35%. CE3. Subjects with elevated serum creatinine level \>2.0mg/dL or undergoing dialysis therapy.
•CE4. Subjects associated with drugs allergy (such as sirolimus, everolimus, stent alloys, contrast medium, heparin, clopidogrel or aspirin).
•CE5. Subjects with bleeding tendency, active peptic ulcer, active gastrointestinal (GI) bleeding or other bleeding diathesis or coagulopathy, or refused a blood transfusion.
•CE6. Subjects with cardiac stroke or with sequelae of stroke. CE7. Subjects with cebral tumor, Cerebral aneurysms, cerebral arteriovenous malformation (AVM), transient ischemic attack (TIA), permanent nerve defects, GI bleeding within 2 months, major operation within 6 weeks, or with abnormal counts of platelet and hemoglobin (Hb): platelet counts less than 1×106/mm3, Hb less than 10g/dL.
•CE8. Subjects plan to undergo any operations within 6 months that may lead to anti-platelet therapy discontinuation.
•CE9. Subjects are suffering from other serious illness, which may cause drop in life expectancy to less than 12 months.
•CE10. Subjects were participating in another study of drug or medical device, which did not meet its primary endpoint.
•CE11. Subject are considered unwilling to understand the trial requirements and refused to follow the treatment procedures.
•CE12. Subject with Heart transplantation.
•AE1. Target lesions with true bifurcation lesion (both main and branch vessel need implantation).
+1 more criteria

Locations (1)

Xijing Hospital

Xi’an, Shanxi, China

Key Dates

Start Date

March 8, 2019

Primary Completion Date

December 1, 2020

Completion Date

December 1, 2021

Last Updated

November 4, 2019

Enrollment

ESTIMATED participants

Conditions

Drug-eluting StentsPercutaneous Coronary InterventionOptical Coherence TomographyST-Elevation Myocardial Infarction

Interventions

percutaneous coronary intervention

PROCEDURE

Contacts

Tao Ling, Doctor

CONTACT

15002955798 lingtao@fmmu.edu.cn

ELEVATE High-Risk PCI Pivotal Study

NCT07001332

High-Risk Percutaneous Coronary Intervention (High-risk PCI)

View study

RECRUITINGPHASE4

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565

Percutaneous Coronary InterventionPeripheral Endovascular Intervention

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

In-stent Repair and Vessel Reaction of STEMI Patients With OCT

Inclusion Criteria

Exclusion Criteria

ELEVATE High-Risk PCI Pivotal Study

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial